Vitafoods Europe international trade show took place last week in Geneva. In this edition, more than 22,000 visitors from almost 120 countries attended the fair to see the latest developments in the nutraceutical field as well as meet industry peers.
On February 5th and 6th, Monteloeder representatives went to Essen, Germany, to participate in the EIC Corporate Day with Evonik. EIC is the European Innovation Council, which organizes meetings and network opportunities for SMEs and start-ups that have received funds from the SME instrument, Fast Track to Innovation and FET-Open programs, giving them the opportunity to present their innovations to large companies in the EU.
Sunday, January 13 has taken place the fifth edition of the 10K Run of the prestigious Organization Rotary Elche. Monteloeder chooses this sporting event fulfilling its solidarity commitment within the Innoprefat project. In addition, their participation is part of their corporate responsibility actions. https://bit.ly/2C66Lti
The worldwide prevalence of obesity has nearly tripled between 1975 and 2016, reaching more than 1.9 billion adults, of which over 650 million were obese.
Every day in our business we are facing health indications in social networks, which are not controlled by EFSA or any other authorities.
We are very happy to inform that we have successfully completed the task regarding microencapsulation of Metabolaid, which is part of the INNOPREFAT project, a H2020 SME instrument phase II project. Microencapsulation has been successfully performed using inulin and maltodextrin as encapsulation agents.
Continue reading INNOPREFAT Milestone Reached: Microencapsulation of Metabolaid through Spray Drying with Inulin and Maltodextrin.
Todays’ healthcare system has recognized the advantages of using big data to improve the quality of healthcare.
The Industry’s Gathering Point Where Science & Strategy Intersect
We are happy to announce that a new study with our weight loss product Metabolaid has been recently published.
In this report, our experts Dr. Nuria Caturla and Dr. Jonathan Jones identify the mechanisms of action of the ingredient, as well as the synergisms of its components.
Specifically, Metabolaid was shown, in mice, to increase AMPK expression in the adipose tissue and liver, which acts as a metabolic switch in the cells, activating lipid degradation and inhibiting adipogenesis. Also, the ingredient acts upon the appetite-regulating gut hormones adiponectin and leptin.
These effects resulted in the treated mice, which were on a high-fat diet, to weigh less, present less body fat, improved lipidic and a glycemic blood profile, and less proinflammatory markers when compared to control mice on the same diet. Another relevant result is that Metabolaid presented similar or better results than Garcinia cambogia, which was used at 2.5 times higher dosage.
The article is open access, feel free to download at the following link: http://www.mdpi.com/